AD Experimental Models Scorecard

AD Experimental Models Scorecard

Introduction

Ad Experimental Models Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

> Rating Scale: Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.

Overview

The AD Experimental Models Scorecard ranks Alzheimer's Disease research models by their predictive validity for human disease. Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.

This scorecard is designed to help researchers select appropriate models for their studies and understand why many standard mouse models have incorrectly predicted therapeutic efficacy, contributing to the high failure rate in AD clinical trials [@sink2015].

Scoring Methodology

AD Experimental Models Scorecard

Introduction

Ad Experimental Models Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

> Rating Scale: Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.

Overview

The AD Experimental Models Scorecard ranks Alzheimer's Disease research models by their predictive validity for human disease. Each model is scored 0-10 across four dimensions: Reproduces Human Pathology, Predicts Clinical Trial Outcomes, Cost & Scalability, and Genetic Relevance. Higher scores indicate better performance.

This scorecard is designed to help researchers select appropriate models for their studies and understand why many standard mouse models have incorrectly predicted therapeutic efficacy, contributing to the high failure rate in AD clinical trials [@sink2015].

Scoring Methodology

| Dimension | Description | Weight |
|-----------|-------------|--------|
| Reproduces Human Pathology | Does the model develop amyloid plaques, neurofibrillary tangles, neuronal loss, and cognitive decline similar to human AD? | 25% |
| Predicts Clinical Trial Outcomes | Has the model correctly predicted success or failure of therapies that worked/failed in humans? | 30% |
| Cost and Scalability | Equipment costs, housing costs, breeding efficiency, and throughput capacity | 20% |
| Genetic Relevance | Does the model use human genes/mutations that cause AD, or risk alleles identified in humans? | 25% |

Model Rankings

Tier 1: Highest Predictive Validity (Total Score: 30-40)

1. Human iPSC Cerebral Organoids

• Total Score: 37/40
• Reproduces Human Pathology: 9/10
• Predicts Clinical Trial Outcomes: 8/10
• Cost and Scalability: 5/10
• Genetic Relevance: 10/10

Strengths:

• Human genetic background
• Three-dimensional brain architecture
• Development of both amyloid and tau pathology
• Patient-specific modeling possible (e.g., APOE ε4 carriers)

• Lacks vascularization and microglia
• Limited size and maturity (typically 2-3 months max)
• High cost and low throughput
• No cognitive behavioral readouts

2. AMP-AD Multi-Omics Data

• Total Score: 35/40
• Reproduces Human Pathology: 10/10
• Predicts Clinical Trial Outcomes: 8/10
• Cost and Scalability: 7/10
• Genetic Relevance: 10/10

Strengths:

• Direct human data - no species translation needed
• Longitudinal cohorts from asymptomatic to advanced AD
• RNA-seq, proteomics, metabolomics, epigenomics
• Identified novel therapeutic targets (e.g., TREM2, PLXNA3)

• Observational only - cannot test interventions
• Postmortem tissue represents end-stage disease
• Complex data analysis requires specialized expertise

3. Patient-Derived CSF/Plasma Biobank Studies

• Total Score: 34/40
• Reproduces Human Pathology: 8/10
• Predicts Clinical Trial Outcomes: 9/10
• Cost and Scalability: 8/10
• Genetic Relevance: 9/10

Tier 2: Good Predictive Value (Total Score: 20-29)

4. APP Knock-in Mice

• Total Score: 28/40
• Reproduces Human Pathology: 7/10
• Predicts Clinical Trial Outcomes: 6/10
• Cost and Scalability: 8/10
• Genetic Relevance: 7/10

5. Sea-AD Single-Cell Atlas

• Total Score: 33/40
• Reproduces Human Pathology: 10/10
• Predicts Clinical Trial Outcomes: 9/10
• Cost and Scalability: 4/10
• Genetic Relevance: 10/10

Tier 3: Moderate Predictive Value (Total Score: 15-19)

6. 5xFAD Mice

• Total Score: 19/40
• Reproduces Human Pathology: 6/10
• Predicts Clinical Trial Outcomes: 3/10
• Cost and Scalability: 9/10
• Genetic Relevance: 4/10

Translation Failure: BACE inhibitors showed cognitive worsening in humans but improved cognition in 5xFAD mice - a major false positive [@muirhead2020].

7. APP/PS1 Mice

• Total Score: 18/40
• Reproduces Human Pathology: 6/10
• Predicts Clinical Trial Outcomes: 3/10
• Cost and Scalability: 9/10
• Genetic Relevance: 4/10

Translation Failure: Similar to 5xFAD - predicted BACE inhibitor benefit that didn't translate to humans.

8. 3xTg-AD Mice

• Total Score: 17/40
• Reproduces Human Pathology: 7/10
• Predicts Clinical Trial Outcomes: 2/10
• Cost and Scalability: 7/10
• Genetic Relevance: 5/10

Summary Comparison Table

| Model | Pathology | Clinical Prediction | Cost | Genetic | TOTAL |
|-------|-----------|--------------------|------|---------|-------|
| APP-KI | 8 | 7 | 7 | 9 | 31 |
| 3xTg-AD | 9 | 5 | 7 | 7 | 28 |
| Sea-AD Atlas | 10 | 9 | 4 | 10 | 33 |
| AMP-AD | 10 | 9 | 3 | 10 | 32 |
| APP/PS1 | 8 | 4 | 9 | 6 | 27 |
| 5xFAD | 9 | 3 | 9 | 5 | 26 |

Key Findings

Models That Correctly Predicted Human Outcomes

Models That Incorrectly Predicted Human Outcomes

The Translation Problem

The fundamental issue is that standard mouse models use:

• Overexpression of amyloid precursor protein (not physiological)
• Aggressive pathology that doesn't match human disease progression
• Young animals when human AD is a disease of aging

Recommendations

For Basic Research

• Prioritize human-derived models (iPSC, organoids)
• Use knock-in models instead of overexpression transgenics
• Incorporate aging and comorbidities

For Drug Discovery

• Validate in multiple models including human systems
• Use organoids for initial screening
• Confirm in knock-in mice before clinical candidate selection

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — Aβ pathology mechanisms
• [Tau Pathology in AD](/mechanisms/tau-pathology) — Tau mechanisms
• [5xFAD Mouse Model](/mechanisms/ad-mouse-models) — Commonly used AD mouse model

References

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |

Overall Confidence: 65%

Model Classification Framework

Scoring Dimensions

Key Findings Summary

| Model Category | Human Pathology | Clinical Prediction | Cost | Genetic Relevance | Total Score | Recommendation |
|----------------|-----------------|---------------------|------|-------------------|-------------|----------------|
| 5xFAD Mouse | 8 | 3 | 9 | 6 | 26 | Moderate |
| rTg4510 | 7 | 4 | 8 | 7 | 26 | Moderate |
| APP/PS1 | 7 | 3 | 9 | 6 | 25 | Moderate |
| iPSC Neurons | 9 | 7 | 4 | 9 | 29 | Moderate |
| 3D Organoids | 8 | 6 | 3 | 9 | 26 | Moderate |
| Aged NHP | 10 | 9 | 1 | 9 | 29 | Moderate | Note: This scorecard provides a framework for evaluating experimental models. Scores reflect current understanding and should be updated as new evidence emerges.